Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells

Journal of Viral Hepatitis

Volumn 21, Issue 8, 2014, Pages 597-603

  Xun, Y H ^a,b,c   Zhang, Y J ^b   Pan, Q C ^a   Mao, R C ^b   Qin, Y L ^b   Liu, H Y ^b   Zhang, Y M ^b   Yu, Y S ^a   Tang, Z H ^a   Lu, M J ^d   Zang, G Q ^a   Zhang, J M ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

hepatitis B virus; hepatitis B virus (HBV) surface antigen; metformin; production; transcriptional regulation

Indexed keywords

CIS ACTING ELEMENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METFORMIN; PEGINTERFERON ALPHA2B; ANTIVIRUS AGENT;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SAFETY; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOTHESIS; LIVER CELL; PRIORITY JOURNAL; VIRUS REPLICATION; BIOSYNTHESIS; DRUG EFFECTS; DRUG REPOSITIONING; HEPG2 CELL LINE; PHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; DRUG REPOSITIONING; HEP G2 CELLS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; METFORMIN; VIRUS REPLICATION;

EID: 84903820219     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12187     Document Type: Article

References (35)

1. Dienstag JL, Hepatitis B,. Virus infection. N Engl J Med 2008; 359 (14): 1486-1500.
2. Stein LL, Loomba R,. Drug targets in hepatitis B virus infection. Infect Disord Drug Targets 2009; 9 (2): 105-116.
3. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1): 167-185.
4. Patient R, Hourioux C, Roingeard P,. Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol 2009; 11 (11): 1561-1570.
5. Chan HL, Thompson A, Martinot-Peignoux M, et al,. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011; 55 (5): 1121-1131.
6. Op den Brouw ML, Binda RS, van Roosmalen MH, et al,. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126 (2): 280-289.
7. Menne S, Roneker CA, Korba BE, Gerin JL, Tennant BC, Cote PJ,. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 2002; 76 (11): 5305-5314. (Pubitemid 34517881)
8. Dougherty AM, Guo H, Westby G, et al,. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother 2007; 51 (12): 4427-4437. (Pubitemid 350209899)
9. Yu W, Goddard C, Clearfield E, et al,. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem 2011; 54 (16): 5660-5670.
10. Chong CR, Sullivan DJ Jr,. New uses for old drugs. Nature 2007; 448 (7154): 645-646. (Pubitemid 47236844)
11. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 (Suppl. 1): S11-S61.
12. Graham GG, Punt J, Arora M, et al,. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50 (2): 81-98.
13. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F,. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122 (6): 253-270.
14. Bergheim I, Guo L, Davis MA, et al,. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130 (7): 2099-2112. (Pubitemid 43816952)
15. Bergheim I, Luyendyk JP, Steele C, et al,. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther 2006; 316 (3): 1053-1061. (Pubitemid 43345278)
16. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A,. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012; 2012: 716404.
17. Romero-Gomez M, Diago M, Andrade RJ, et al,. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50 (6): 1702-1708.
18. Lim JY, Oh MA, Kim WH, Sohn HY, Park SI,. AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol 2012; 227 (3): 1081-1089.
19. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G,. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30 (5): 750-758.
20. Chen HP, Shieh JJ, Chang CC, et al,. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013; 62 (4): 606-615.
21. Quasdorff M, Protzer U,. Control of hepatitis B virus at the level of transcription. J Viral Hepatitis 2010; 17 (8): 527-536.
22. Bar-Yishay I, Shaul Y, Shlomai A,. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int 2011; 31 (3): 282-290.
23. Wakui Y, Inoue J, Ueno Y, et al,. Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone. Biochem Biophys Res Commun 2010; 396 (2): 508-514.
24. Bader T, Korba B,. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res 2010; 86 (3): 241-245.
25. Mao R, Zhang J, Jiang D, et al,. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 2011; 85 (2): 1048-1057.
26. Zhang X, Zhang E, Ma Z, et al,. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011; 53 (5): 1476-1485.
27. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-2695. (Pubitemid 41007823)
28. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351 (12): 1206-1217. (Pubitemid 39296307)
29. Zoulim F,. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res 2012; 96 (2): 256-259.
30. Iser DM, Warner N, Revill PA, et al,. Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol 2010; 84 (12): 5860-5867.
31. Warner N, Locarnini S,. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48 (1): 88-98. (Pubitemid 351975534)
32. Qin J, Zhai J, Hong R, et al,. Prospero-related homeobox protein (Prox1) inhibits hepatitis B virus replication through repressing multiple cis regulatory elements. J Gen Virol 2009; 90 (Pt 5): 1246-1255.
33. Kim BK, Lim SO, Park YG,. Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication. Hepatology 2008; 48 (2): 361-373.
34. Lin YC, Hsu EC, Ting LP,. Repression of hepatitis B viral gene expression by transcription factor nuclear factor-kappaB. Cell Microbiol 2009; 11 (4): 645-660.
35. He F, Chen EQ, Liu L, et al,. Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA. Liver Int 2012; 32 (5): 742-751.